aDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN;
bDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD;
cCenter for Biostatistics in AIDS Research, Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA;
dDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD;
eElizabeth Glaser Pediatric AIDS Foundation, Washington, DC;
fMakerere University—Johns Hopkins University Research Collaboration, Kampala, Uganda;
gDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC;
hDepartment of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe;
iUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe;
jDepartment of Pediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa;
kDivision of AIDS, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, MD;
lMaternal and Pediatric Infectious Disease Branch, Division of Extramural Research, Eunice Kennedy Shriver Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD;
mFHI 360, Durham, NC;
nDepartment of Pediatrics and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA;
oCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA;
pUniversity of North Carolina Project-Malawi, Kamuzu Central Hospital, Lilongwe, Malawi;
qDepartment of Obstetrics and Gynecology, College of Medicine, University of Malawi, Blantyre, Malawi;
rDepartment of Obstetrics and Gynaecology, Centre for the AIDS Programme of Research in South Africa and School of Clinical Medicine, College of Health Sciences, University of KwaZulu Natal, Durban, South Africa;
sDepartment of Obstetrics and Gynecology, Byramjee Jeejeebhoy Government Medical College and Johns Hopkins Clinical Trials Unit, Pune, India;
tDepartment of Pediatrics and Child Health, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa;
uDepartment of Pediatrics, Kilimanjaro Christian Medical Centre and Kilimanjaro Christian Medical University College, Moshi, Tanzania;
vWits Reproductive Health and HIV Institute, Johannesburg, South Africa;
wPerinatal HIV Research Unit, Chris Baragwanath Hospital, Johannesburg, South Africa;
xDepartment of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; and
yCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Correspondence to: Patricia M. Flynn, MD, 262 Danny Thomas Place, Memphis, TN 38105 (e-mail: [email protected]).
Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) network was provided by the National Institute of Allergy and Infectious Diseases (NIAID), with cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC), and UM1AI106716 (IMPAACT LC), and NICHD, contract number HHSN275201800001I. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Study drugs were provided by AbbVie, Boehringer-Ingelheim, Gilead Sciences, and ViiV/GlaxoSmithKline.
Data was presented in part at the 22nd International AIDS Conference, July 23–27, 2018, Amsterdam, the Netherlands, and the 10th International Workshop of HIV Pediatrics, July 20–21, Amsterdam, the Netherlands.
P.M.F. is a consultant for Merck. The remaining authors have no conflicts of interest to disclose.
ClinicalTrials.gov: NCT01061151; Completed.
